Last10K.com

Acelity L.P. Inc. (1557939) SEC Filing 10-K Annual report for the fiscal year ending Wednesday, December 31, 2014

Acelity L.P. Inc.

CIK: 1557939



ACELITY L.P. INC. REPORTS
FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS FOR 2014

- Fourth quarter revenue grew 6.5% compared to the prior-year period, on a constant currency basis

- Fourth quarter 2014 Adjusted EBITDA from continuing operations1 grew 5.4% compared to the prior-year period, on a constant currency basis

- Fourth quarter loss from continuing operations was $30.9 million compared to $52.0 million for the prior-year period

“I am pleased with our execution in the fourth quarter, which has again led to solid financial performance and continued momentum in the business, particularly within Advanced Wound Therapeutics devices where we reached record volumes,” said Joe Woody, President and Chief Executive Officer. “Our Systagenix integration continues as planned and is translating into a strategic growth platform for Acelity. We continue to make focused investments in market development, geographic expansion and innovation to further accelerate growth for the long term.”

Results of the fourth quarter and year ended December 31, 2014

Acelity revenue for the fourth quarter of 2014 was $482.7 million, up from the prior-year period by 4.4% as reported and 6.5% on a constant currency basis.
Advanced Wound Therapeutics ("AWT") revenue was $369.0 million, up 7.6% as reported and 10.3% on a constant currency basis, compared to the prior-year period. Excluding Systagenix, AWT revenue grew 6.0% on a constant currency basis due primarily to NPWT volume growth during the quarter. The remaining AWT growth was fueled by the fourth quarter 2013 addition of Systagenix to our global portfolio of product offerings.
Regenerative Medicine revenue was $109.3 million, down 5.9% as reported and 5.4% on a constant currency basis, compared to the prior-year period. The decline was primarily due to lower volumes associated with hernia repair procedures, partially offset by growth in breast reconstruction and growth in international markets.

Adjusted EBITDA from continuing operations for the fourth quarter of 2014 increased 3.6% to $198.3 million from $191.5 million in the prior-year period. The growth rate of Adjusted EBITDA from continuing operations was negatively impacted by 1.8% due to unfavorable movements in foreign exchange rates. Our loss from continuing operations for the fourth quarter of 2014 was $30.9 million, compared to $52.0 million in the prior-year period.

Acelity revenue for the year ended December 31, 2014, was $1.866 billion, up from the prior year by 7.7% as reported and 8.3% on a constant currency basis.
AWT revenue was $1.420 billion, up 10.3% as reported and 11.1% on a constant currency basis, compared to the prior year. Year-over-year revenue growth was primarily the result of our acquisition of Systagenix in the fourth quarter of 2013. Excluding Systagenix, our AWT business declined 1.9% on a constant currency basis due primarily to lower average pricing resulting from increased competition, healthcare reform and declining reimbursement. Higher volumes from our North America NPWT business and continued growth in the fastest growing markets around the globe partially offset this decline.
Regenerative Medicine revenue was $428.1 million, down 3.2% as reported and 3.1% on a constant currency basis, compared to the prior year. This decline was due primarily to reduced volumes in our hernia repair business, partially offset by growth in our breast reconstruction business and continued international growth.

Adjusted EBITDA from continuing operations for the year ended December 31, 2014, declined 0.8% to $712.1 million from $717.6 million in the prior year. On a constant currency basis, Adjusted EBITDA from continuing operations for the year ended



The following information was filed by Acelity L.P. Inc. on Tuesday, February 17, 2015 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Acelity L.P. Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Acelity L.P. Inc..

Continue

Assess how Acelity L.P. Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Acelity L.P. Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2015 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information
Schedule Ii
Schedule Ii (details)
Consolidated Balance Sheets
Consolidated Statements Of Cash Flows
Consolidated Statements Of Comprehensive Income (loss)
Consolidated Statements Of Comprehensive Income (loss) (parenthetical)
Consolidated Statements Of Equity
Consolidated Statements Of Equity (parenthetical)
Consolidated Statements Of Operations
Accounting For Goodwill And Other Non-current Assets
Accounting For Goodwill And Other Non-current Assets (tables)
Accounting For Goodwill And Other Non-current Assets Debt Issuance Costs (details)
Accounting For Goodwill And Other Non-current Assets Schedule Of Definite-lived And Indefinite-lived Intangible Assets (details)
Accounting For Goodwill And Other Non-current Assets Schedule Of Estimated Amortization Expense (details)
Accounting For Goodwill And Other Non-current Assets Schedule Of Goodwill (details)
Acquisitions And Divestitures
Acquisitions And Divestitures Acquisitions (details)
Acquisitions And Divestitures Acquisitions And Divestitures (tables)
Acquisitions And Divestitures Business Acquisition, Pro Forma (details)
Acquisitions And Divestitures Divestitures (details)
Commitments And Contingencies
Commitments And Contingencies (details)
Derivative Financial Instruments And Fair Value Measurements
Derivative Financial Instruments And Fair Value Measurements (tables)
Derivative Financial Instruments And Fair Value Measurements - Derivative Financial Instruments (details)
Derivative Financial Instruments And Fair Value Measurements - Fair Value And Balance Sheet Locations (details)
Derivative Financial Instruments And Fair Value Measurements - Gain (loss) On Derivatives (details)
Equity
Equity (details)
Guarantor Condensed Consolidating Financial Statements
Guarantor Condensed Consolidating Financial Statements (tables)
Guarantor Condensed Consolidating Financial Statements - Condensed Consolidated Balance Sheet (details)
Guarantor Condensed Consolidating Financial Statements - Condensed Consolidated Cash Flow (details)
Guarantor Condensed Consolidating Financial Statements - Condensed Consolidated Statement Of Operations And Comprehensive Income (loss) (details)
Incentive Compensation Plans
Incentive Compensation Plans - Equity-based Compensation Expense And 401(k) Recognized Costs (details)
Incentive Compensation Plans - Equity-based Plans (details)
Incentive Compensation Plans Incentive Compensation Plans (tables)
Income Taxes (benefit)
Income Taxes (benefit) (tables)
Income Taxes (benefit) - Reconciliation Of The Allowance For Uncertain Tax Positions (details)
Income Taxes (benefit) - Schedule Of Components Of Income Tax Expense (benefit) (details)
Income Taxes (benefit) - Schedule Of Deferred Tax Assets And Liabilities (details)
Income Taxes (benefit) - Schedule Of Effective Inome Tax Rate Reconciliation (details)
Income Taxes (benefit) - Schedule Of Income Before Income Tax, Domestic And Foreign (details)
Leasing Obligations
Leasing Obligations (tables)
Leasing Obligations - Narrative (details)
Leasing Obligations - Schedule Of Future Minimum Lease Payments (details)
Long-term Debt
Long-term Debt (details)
Long-term Debt (tables)
Other Comprehensive Income (loss)
Other Comprehensive Income (loss) (details)
Other Comprehensive Income (loss) (tables)
Quarterly Financial Data (unaudited)
Quarterly Financial Data (unaudited) (details)
Quarterly Financial Data (unaudited) (tables)
Related Party Transactions
Related Party Transactions (details)
Segment And Geographic Information
Segment And Geographic Information (details)
Segment And Geographic Information (tables)
Segment And Geographic Information Information On Segment Assets (details)
Segment And Geographic Information Schedule Of Depreciation And Other Amortization (details)
Segment And Geographic Information Schedule Of Gross Capital Expenditures (details)
Segment And Geographic Information Schedule Of Information On The Geographical Location Of Select Financial Information (details)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (details)
Summary Of Significant Accounting Policies (policies)
Summary Of Significant Accounting Policies (tables)
Summary Of Significant Accounting Policies - Schedule Of Concentrations Of Accounts Receivable (details)
Supplemental Balance Sheet Data
Supplemental Balance Sheet Data (tables)
Supplemental Balance Sheet Data - Accounts Receivable, Net (details)
Supplemental Balance Sheet Data - Accrued Expenses And Other (details)
Supplemental Balance Sheet Data - Inventories, Net (details)
Supplemental Balance Sheet Data - Net Property, Plant, And Equipment (details)
CIK: 1557939
Form Type: 10-K Annual Report
Accession Number: 0001557939-15-000014
Submitted to the SEC: Tue Mar 10 2015 7:59:34 PM EST
Accepted by the SEC: Wed Mar 11 2015
Period: Wednesday, December 31, 2014
Industry: Surgical And Medical Instruments And Apparatus

External Resources:

Bookmark the Permalink:
https://last10k.com/sec-filings/1557939/0001557939-15-000014.htm